GlassScriptPhysician profile
Aaron M Miller
NPI 1649406547
$6,532.68
in general payments reported to CMS, 2019-2025
30 companies · $729 in 2025
The $729 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $720 · 2021: $922 · 2022: $944 · 2023: $1,064 · 2024: $977 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $918.76 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $855.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $769.10 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $707.37 | 2019-2025 | |
| Abbvie INC. | $613.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $483.33 | 2019-2023 | Fasenra |
| Electromed, INC. | $345.54 | 2019-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $213.82 | 2019-2024 | Dificid, Verquvo, Zerbaxa |
| Novo Nordisk INC | $202.32 | 2019-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $201.83 | 2020-2025 | Lifevest |
| Paratek Pharmaceuticals, INC. | $173.26 | 2020-2024 | Nuzyra |
| Gilead Sciences, INC. | $171.12 | 2021-2023 | Veklury |
| Lundbeck LLC | $154.98 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $123.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.69 | 2022-2025 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.32 | 2021-2023 | Ultomiris |
| Allergan, INC. | $75.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $61.81 | 2019 | |
| Melinta Therapeutics, LLC | $48.61 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.54 | 2019-2021 | |
| Abbott Laboratories | $24.02 | 2022 | |
| Kestra Medical Technology Services, INC. | $23.93 | 2023 | Assure Wcd |
| Takeda Pharmaceuticals U.S.A., INC. | $22.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.32 | 2019 | |
| Insmed, INC. | $21.78 | 2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Nabriva Therapeutics, Plc | $19.47 | 2021 | |
| Amgen INC. | $16.81 | 2019 | |
| Smith+Nephew, INC. | $16.22 | 2020 | |
| Tactile Systems Technology INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.